Today, the DAPA-CKD findings proved to be comparable, if somewhat different, from the April 2019 results for canagliflozin (Invokana, Janssen) in CREDENCE, a landmark study that found a 30% risk ...

The DAPA-CKD trial randomly assigned 4304 patients with CKD but without an enrollment criterion for the presence of diabetes. The full study results, reported at the European Society for ...

That's the main result of the DAPA-CKD trial presented in a Hot Line session today at ESC Congress 2020.1 The DAPA-CKD trial tested the hypothesis that treatment with dapagliflozin is superior to ...

For those interested in DAPA-CKD, the original trial was published in The New England Journal of Medicine in September of last year. The purpose of this study was to look at the time-to-event and ...

WILMINGTON, Del.--(BUSINESS WIRE)--The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for FARXIGA (dapagliflozin) in patients with chronic ...

A new subgroup analysis from the ground-breaking DAPA-CKD Phase III trial showed that AstraZeneca’s Farxiga (dapagliflozin), on top of standard of care, reduced the composite of worsening of kidney ...

AstraZeneca has announced that the phase 3 DAPA-CKD trial for dapagliflozin (Farxiga) in patients with chronic kidney disease has been halted early because of overwhelming efficacy of the drug ...

“The DAPA-CKD trial has shown dapagliflozin’s potential as a long-awaited new treatment option for patients with chronic kidney disease,” Hiddo J.L. Heerspink, PhD, clinical pharmacologist ...

Please provide your email address to receive an email when new articles are posted on . The phase 3 DAPA-CKD trial assessing the benefit of the SGLT2 inhibitor dapagliflozin in adults with chronic ...

--(BUSINESS WIRE)-- High-level results from FARXIGA®’s (dapagliflozin) Phase III DAPA-CKD trial showed a statistically significant and clinically meaningful effect on its primary endpoint of a ...

A new subgroup analysis from the ground-breaking DAPA-CKD phase III trial showed that AstraZeneca’s Farxiga (dapagliflozin), on top of standard of care, reduced the composite of worsening of kidney ...

AZ halted DAPA-CKD in July after revealing that Farxiga (dapagliflozin) met its objective of slowing the worsening of renal function and cut the risk of death in patients with chronic kidney ...